Therapy News and Research

RSS

New path involving "innocent spectators" to defeat systemic sclerosis

There is a new path to defeat systemic sclerosis, also called scleroderma because of the hardening of the skin of the patients (from Greek skleros, "hard", and derma, "skin"). This path involves the B-cell of the immune system, so far only considered "innocent spectators," as Catholic University rheumatologist Gianfranco Ferraccioli, among the authors of the important research, puts it.

14 Jun 2010

UCB announces availability of Vimpat oral solution formulation

UCB today announced the availability of an oral solution formulation of Vimpat- (lacosamide) C-V, an antiepileptic drug (AED) for add-on treatment of partial-onset seizures in people with epilepsy age 17 years and older. Vimpat 10 mg/mL solution is now available in U.S. pharmacies.

14 Jun 2010

Ingen Technologies' new SMART Nasal Cannula unveiled at Alpha-1 19th National Education Conference

Ingen Technologies, Inc., a medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S. and $8 billion globally, unveiled their new SMART Nasal Cannula in Orlando-Florida last week at the Alpha-1 19th Annual National Education Conference.

14 Jun 2010

Esperion, Cleveland Clinic collaborate to research new HDL therapies for cardiovascular disease

Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the establishment of a collaborative research agreement with Cleveland Clinic, one of the world's leading academic medical centers. The collaboration will work to advance research targeting new HDL therapies to treat cardiovascular disease.

14 Jun 2010

Calistoga Pharmaceuticals presents CAL-101 PI3K inhibitor data at European Hematology Association Congress

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today presented preclinical and clinical data on CAL-101, the Company's oral, delta selective PI3K inhibitor at the 15th Congress of the European Hematology Association in Barcelona, Spain.

14 Jun 2010

Telormedix initiates Phase I/II clinical study of TMX-101 for treating NMIBC

Telormedix, a clinical stage biopharmaceutical company focused on targeted immunity in the treatment of cancer and other diseases, today announced the start of a Phase I/II clinical study of TMX-101 for the treatment of Non-Muscle Invasive Bladder Cancer. TMX-101 is an immunotherapeutic compound and Telormedix has already recruited the first patients for this clinical study.

14 Jun 2010

New research evaluating substantial disease burden of PNH presented at European Hematology Association

Alexion Pharmaceuticals, Inc. today announced new research evaluating the substantial disease burden of paroxysmal nocturnal hemoglobinuria, an ultra-rare blood disorder, in patients worldwide. The International PNH Registry, involving 580 patients from 99 sites in 14 countries as of May 2010, found that the debilitating symptoms and life-threatening complications of PNH are similar across patient populations around the world.

14 Jun 2010

Biodel announces schedule for presentations at 70th Scientific Sessions of American Diabetes Association

Biodel Inc. announced today that the following oral and poster presentations describing results from studies of the company's product candidates will be presented during the 70th Scientific Sessions of the American Diabetes Association this month in Orlando, Florida:

14 Jun 2010

Patients beginning therapy on popular osteoporosis drugs discontinue treatment within 6 months: Report

According to a recent analysis by SDI, a leading healthcare market insight and analytics firm, about half of patients beginning therapy on popular osteoporosis drugs discontinue their treatment within 6 months. Amgen's Prolia, which was recently approved for postmenopausal women with osteoporosis at high risk of fracture, or patients who could not tolerate other osteoporosis therapies, is the newest product to enter the market. Prolia differs from existing therapies as it is given every 6 months via injection.

14 Jun 2010

McDermott's Health Industry Advisory Practice Group recognized as Health Team of the Year

McDermott Will & Emery is pleased to announce the Firm's Health Industry Advisory Practice Group was honored as the "Health Team of the Year" during the Chambers USA Awards in New York on June 10, 2010. This is the first time an award in this category has been given on a national basis by Chambers, and McDermott was selected over four other finalist firms.

14 Jun 2010

Dr. Carolle Jean-Murat continues to provide much needed services to the people of Haiti

Dr. Carolle Jean-Murat, a San Diego based OB-Gyn surgeon and intuitive healer is returning July 1st to Haiti, the land of her birth, to continue assisting in the humanitarian effort for that devastated country. She has assisted in coordinating a team of 50 doctors, dentists and other emergency medical professionals to accompany her to provide much needed services to the people of Haiti.

14 Jun 2010

TF12 antibody targets EGP-1 expressed in epithelial cancer: Immunomedics

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that TF12, in combination with radiolabeled peptides, produced specific, fast, high-contrast imaging and pretargeted radioimmunotherapy of epithelial cancers that include cancers of the prostate and the ovary.

14 Jun 2010

Research highlights importance of CT scanning in severe asthma patients

A new study led by University of Leicester researchers at Glenfield Hospital suggests that CT scans may be the way forward for monitoring progression of severe asthma as well as checking how it is responding to treatment.

14 Jun 2010

Researchers report 4 pillars of preventive medicine for AD

Although effective treatment for Alzheimer's disease has been slow to emerge, there has been substantial progress in identifying AD risk factors and developing treatments that might delay or prevent onset of the disease. In a Special Issue of the Journal of Alzheimer's Disease, "Basics of Alzheimer's Disease Prevention," researchers report on key findings that point towards possible significant interventions.

14 Jun 2010

Phase III study of REVLIMID for treating patients with multiple myeloma shows improvement in PFS

Celgene International Sàrl announced that data from the planned second interim analysis (median follow-up of 21 months) of a phase III, randomized, double-blind study of continuous REVLIMID (lenalidomide) for the treatment of elderly patients with newly diagnosed multiple myeloma show improvement in progression-free survival, the primary endpoint of the study.

14 Jun 2010

Telmisartan reduces hypertension, cardiovascular risk in ACE-intolerant patients: Boehringer Ingelheim

Telmisartan, an angiotensin receptor blocker, is one of the best researched drugs worldwide. It has been studied in clinical trials in more than 50,000 patients. Its positive safety profile has been confirmed also in a market exposure of 34.5 million patient years. Convincing safety data for patients with a high cardiovascular risk were collected in the three long-term outcome trials ONTARGET, PRoFESS and TRANSCEND which followed some of the patients for up to five years.

14 Jun 2010

Researchers find new way to prevent blindness caused by retinitis pigmentosa

Researchers at the University of Oklahoma Health Sciences Center have found a way to use a radical new type of gene therapy to prevent blindness caused by retinitis pigmentosa, giving hope to the estimated 100,000 Americans who suffer from this debilitating disease.

14 Jun 2010

Olfactory function tests could help in treating patient in early stages of PD

A fast, simple and non invasive test of the ability to smell may be an important tool to screen people who are likely to develop Parkinson's disease, in which motor symptoms only become evident at a later stage of the disease, a German scientist will tell the annual conference of the European Society of Human Genetics today (Saturday).

14 Jun 2010

CNVs increases patients' susceptibility to severe sepsis

Genetic makeup has been identified as a key factor leading to the development of sepsis, a systemic inflammatory reaction that occurs during infection. Sepsis is considered severe when associated with organ dysfunction.

14 Jun 2010

Asymptomatic perioperative arrhythmias can lead to sudden cardiac death after surgery: Researchers

Vascular surgery may be accompanied by cardiovascular complications, like ventricular tachyarrhythmia. Though, these arrhythmias initially might be asymptomatic, they can lead to increased risk for late sudden cardiac death after surgery. Researchers from the Netherlands believe that cardiac high-risk patients with new-onset perioperative VT might benefit from preemptive cardioverter defibrillator implantation in addition to optimal focused medical therapy.

14 Jun 2010

Therapy News and Research

New path involving "innocent spectators" to defeat systemic sclerosis

UCB announces availability of Vimpat oral solution formulation

Ingen Technologies' new SMART Nasal Cannula unveiled at Alpha-1 19th National Education Conference

Esperion, Cleveland Clinic collaborate to research new HDL therapies for cardiovascular disease

Calistoga Pharmaceuticals presents CAL-101 PI3K inhibitor data at European Hematology Association Congress

Telormedix initiates Phase I/II clinical study of TMX-101 for treating NMIBC

New research evaluating substantial disease burden of PNH presented at European Hematology Association

Biodel announces schedule for presentations at 70th Scientific Sessions of American Diabetes Association

Patients beginning therapy on popular osteoporosis drugs discontinue treatment within 6 months: Report

McDermott's Health Industry Advisory Practice Group recognized as Health Team of the Year

Dr. Carolle Jean-Murat continues to provide much needed services to the people of Haiti

TF12 antibody targets EGP-1 expressed in epithelial cancer: Immunomedics

Research highlights importance of CT scanning in severe asthma patients

Researchers report 4 pillars of preventive medicine for AD

Phase III study of REVLIMID for treating patients with multiple myeloma shows improvement in PFS

Telmisartan reduces hypertension, cardiovascular risk in ACE-intolerant patients: Boehringer Ingelheim

Researchers find new way to prevent blindness caused by retinitis pigmentosa

Olfactory function tests could help in treating patient in early stages of PD

CNVs increases patients' susceptibility to severe sepsis

Asymptomatic perioperative arrhythmias can lead to sudden cardiac death after surgery: Researchers

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News